iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
0.7500
+0.0500 (7.14%)
At close: Apr 23, 2025, 4:00 PM
0.7310
-0.0190 (-2.53%)
After-hours: Apr 23, 2025, 4:53 PM EDT
iBio, Inc. Employees
iBio, Inc. had 16 employees as of June 30, 2024. The number of employees decreased by 10 or -38.46% compared to the previous year.
Employees
16
Change (1Y)
-10
Growth (1Y)
-38.46%
Revenue / Employee
$23,438
Profits / Employee
-$1,206,438
Market Cap
7.41M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
IBIO News
- 1 day ago - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - GlobeNewsWire
- 16 days ago - iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - GlobeNewsWire
- 2 months ago - iBio to Begin Trading on the Nasdaq Stock Exchange - GlobeNewsWire
- 2 months ago - iBio Reports Fiscal Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio - GlobeNewsWire
- 5 months ago - iBio Reports Fiscal First Quarter 2025 Financial Results - GlobeNewsWire
- 7 months ago - iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - iBio to Participate in Upcoming Investor Conferences - GlobeNewsWire